Department of Otolaryngology-Head & Neck Surgery, Chang Gung Memorial Hospital, Tao-Yuan, Taiwan.
Ann Surg Oncol. 2010 Jul;17(7):1945-56. doi: 10.1245/s10434-010-0926-2. Epub 2010 Mar 23.
Both activin A, a member of transforming growth factor beta superfamily, and its inhibitor follistatin have been shown to be overexpressed in various cancers. We examined the potential role of activin A and follistatin in tissue and blood samples from patients with oral squamous cell carcinoma.
For activin A and follistatin, the expression of tissue samples from 92 patients was examined by immunohistochemical study, and the serum levels of blood samples from 111 patients and 91 healthy controls were measured by enzyme-linked immunosorbent assay.
We found that overexpression of immunohistochemically detected activin A was correlated with positive N stage, poor histological differentiation, and perineural invasion (P = 0.029, 0.002, and 0.014, respectively). In survival analyses, patients with oral squamous cell carcinoma, whose tumors overexpressed activin A, had a worse prognosis for overall survival and disease-free survival (P = 0.009 and 0.007). However, expression of follistatin in tumor was not correlated with overall survival or disease-free survival. Serum activin A and follistatin levels in 111 untreated patients were neither significantly different from those of 91 control samples nor associated with any clinicopathological manifestations. In vitro suppression of activin A expression in OC3 cells using specific interfering RNA-attenuated cell proliferation, migration, and invasiveness.
These findings suggest that activin A overexpression in oral squamous cell carcinomas is associated with patients' survival and may contribute to tumor progression and metastasis.
转化生长因子-β超家族成员激活素 A 及其抑制剂滤泡抑制素在各种癌症中均过度表达。我们研究了激活素 A 和滤泡抑制素在口腔鳞状细胞癌患者组织和血液样本中的潜在作用。
采用免疫组织化学方法检测 92 例患者组织样本中激活素 A 和滤泡抑制素的表达,采用酶联免疫吸附试验检测 111 例患者和 91 例健康对照者血清样本中的血清水平。
我们发现,免疫组化检测到的激活素 A 过表达与 N 分期阳性、组织学分化差和神经周围浸润相关(P=0.029、0.002 和 0.014)。在生存分析中,激活素 A 过表达的口腔鳞状细胞癌患者的总生存率和无病生存率较差(P=0.009 和 0.007)。然而,肿瘤中滤泡抑制素的表达与总生存率或无病生存率无关。111 例未经治疗的患者的血清激活素 A 和滤泡抑制素水平与 91 例对照样本均无显著差异,也与任何临床病理表现无关。在 OC3 细胞中用特异性干扰 RNA 抑制激活素 A 的表达,可减弱细胞的增殖、迁移和侵袭能力。
这些发现提示,口腔鳞状细胞癌中激活素 A 的过表达与患者的生存有关,可能促进肿瘤的进展和转移。